


## Tiotropium/olodaterol versus tiotropium in Japanese patients with COPD: results from the DYNAGITO study [Corrigendum]

Ichinose M, Nishimura M, Akimoto M, et al. *Int J Chron Obstruct Pulmon Dis.* 2018;13:2147–2156. On page 2152, Figure 3 should be presented as follows:



**Figure 3** Annualized rate of COPD exacerbations by treatment group.

**Notes:** Error bars represent the 99% CI for rate of moderate-to-severe COPD exacerbations and the 95% CI for rate of severe COPD exacerbations. Listed values are RR (CI: \*99% CI; ^95% CI), p-value. Negative binominal model, adjusted for treatment exposure. The duration of an event is not included in the calculation of a patient's exposure.

**Abbreviations:** OLO, olodaterol; TIO, tiotropium; RR, rate ratio.

The International Journal of COPD is an international, peer-reviewed journal of therapeutics and pharmacology focusing on concise rapid reporting of clinical studies and reviews in COPD. Special focus is given to the pathophysiological processes underlying the disease, intervention programs, patient focused education, and self management protocols.

Submit your manuscript here: <http://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journal>

This journal is indexed on PubMed Central, MedLine and CAS. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.